Phreesia’s (PHR) “Buy” Rating Reaffirmed at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Phreesia (NYSE:PHR) in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a $34.00 price objective on the stock.

Several other equities analysts also recently weighed in on PHR. JMP Securities reiterated a market outperform rating and set a $30.00 target price on shares of Phreesia in a research report on Friday, August 30th. Truist Financial restated a buy rating and issued a $29.00 target price on shares of Phreesia in a report on Monday, July 1st. DA Davidson reaffirmed a buy rating and set a $32.00 price target on shares of Phreesia in a research note on Thursday. KeyCorp decreased their price target on shares of Phreesia from $27.00 to $25.00 and set an overweight rating on the stock in a report on Thursday, July 11th. Finally, Stephens restated an overweight rating and set a $28.00 price objective on shares of Phreesia in a report on Friday, May 31st. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus price target of $30.54.

Phreesia Trading Up 6.3 %

Shares of PHR opened at $25.69 on Thursday. Phreesia has a fifty-two week low of $12.05 and a fifty-two week high of $30.70. The company has a market capitalization of $1.47 billion, a PE ratio of -11.84 and a beta of 0.93. The stock has a fifty day moving average of $23.33 and a two-hundred day moving average of $22.82. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.76 and a current ratio of 1.76.

Insider Buying and Selling at Phreesia

In other news, SVP David Linetsky sold 1,820 shares of the company’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total value of $43,206.80. Following the completion of the sale, the senior vice president now owns 202,218 shares of the company’s stock, valued at $4,800,655.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, COO Evan Roberts sold 1,669 shares of the firm’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $23.74, for a total transaction of $39,622.06. Following the completion of the sale, the chief operating officer now directly owns 753,234 shares of the company’s stock, valued at approximately $17,881,775.16. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP David Linetsky sold 1,820 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total transaction of $43,206.80. Following the completion of the transaction, the senior vice president now owns 202,218 shares in the company, valued at approximately $4,800,655.32. The disclosure for this sale can be found here. Insiders have sold 29,337 shares of company stock valued at $736,750 over the last three months. 5.80% of the stock is owned by company insiders.

Institutional Trading of Phreesia

Several large investors have recently modified their holdings of the business. nVerses Capital LLC boosted its holdings in Phreesia by 76.5% in the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after purchasing an additional 1,300 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Phreesia by 5,462.3% during the 4th quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock valued at $89,000 after buying an additional 3,769 shares during the last quarter. EntryPoint Capital LLC purchased a new position in shares of Phreesia during the 1st quarter valued at approximately $169,000. Quadrature Capital Ltd bought a new stake in shares of Phreesia in the first quarter worth $202,000. Finally, Lombard Odier Asset Management USA Corp bought a new stake in shares of Phreesia in the second quarter worth $202,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.